Table 2.
Clinical trials of drugs and treatments that target immunosuppressive factors (either as monotherapy or in combination) in chronic and acute myeloid leukemia, either ongoing or completed trials, according to clinicaltrials.gov database [224].
| Target | Drug | Phase | Trial Number (clinicaltrials.gov) |
Malignancy |
|---|---|---|---|---|
| PD-L1 | Avelumab | 1–2 | NCT03390296 | AML |
| 1–2 | NCT02767063 | CML | ||
| Atezolizumab | 1 | NCT02892318, NCT03922477 | AML | |
| 1–2 | NCT03730012 | AML | ||
| Durvalumab | 2 | NCT02775903 | AML | |
| PD-1 | Nivolumab | 1 | NCT01822509 | CML, AML |
| 1 | NCT02011945 | CML | ||
| 1 | NCT04361058 | AML | ||
| 1–2 | NCT03825367 | AML | ||
| 2 | NCT02397720, NCT02464657, NCT02275533, NCT02532231 | AML | ||
| Pembrolizumab | 1 |
NCT02981914, NCT03969446, NCT03286114 |
AML | |
| 1–2 | NCT03761914, NCT02996474 | AML | ||
| 2 |
NCT03769532, NCT02768792 NCT02845297, NCT04284787, NCT02708641 |
AML | ||
| PDR001 | 1 | NCT03066648 | AML | |
| Tislelizumab | 2 | NCT04541277 | AML | |
| CTLA-4 | Ipilimumab | 1 | NCT00060372 | CML, AML |
| 1 |
NCT03912064, NCT01757639 NCT01757639, NCT02890329 |
AML | ||
| PD-1 + CTLA-4 | Nivolumab + ipilimumab |
1 | NCT01822509, NCT03600155 | CML, AML |
| 2 | NCT02397720 | AML | ||
| TIM-3 | MBG453 | 1 | NCT03940352, NCT03066648 | AML |
| 2 | NCT04150029 | AML | ||
| CD47 | ALX148 | 1–2 | NCT04755244 | AML |
| Magrolimab | 1–2 | NCT04435691 | AML | |
| IBI188 | 1–2 | NCT04485052 | AML | |
| TJ011133 | 1–2 | NCT04202003 | AML | |
| CD25 (Treg) | ADCT-301 | 2 | NCT04639024 | AML |
| arginine | PEG-BCT-100 (recombinant arginase 1) |
2 | NCT02899286 | AML |